Irina Shahapuni, Matthieu Monge, Roxana Oprisiu, Hakim Mazouz, Pierre-François Westeel, Philippe Morinière, Ziad Massy, Gabriel Choukroun, Albert Fournier
Calcimimetics suppress the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. Cinacalcet (Sensipar/Mimpara), Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is, in association with higher dose of a calcium-based oral phosphate binder, a well-tolerated and effective alternative to standard treatments such as vitamin D derivatives in association with a non-calcium-based oral phosphate binder...
June 2006: Nature Clinical Practice. Nephrology